89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
14 mai 2024 08h00 HE
|
89bio, Inc.
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mai 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, May 10, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h05 HE
|
89bio, Inc.
–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients– –Expect to initiate ENLIGHTEN-Cirrhosis trial this...
89bio to Participate in the BofA Securities 2024 Health Care Conference
08 mai 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
02 mai 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
17 avr. 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 avr. 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
27 mars 2024 08h00 HE
|
89bio, Inc.
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and...
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
12 mars 2024 08h00 HE
|
89bio, Inc.
—Co-primary endpoints in ENLIGHTEN-Fibrosis assessed at week 52 will potentially support accelerated approval in non-cirrhotic MASH (fibrosis stage F2-F3) patients— —ENLIGHTEN-Cirrhosis, the second...
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08 mars 2024 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization...